Maharaj N, Uppada DR, Reddy N, Reddy P, et al. Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study. Arthritis Res Ther 2024;26:225.
PMID: 39709462